CancerNCT05673018
Galleri® in the Medicare Population.
A study testing Multi-Cancer Early Detection Test (Galleri®) in people with Cancer, run by GRAIL, Inc. at 72 sites in United States.
Trial summary
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer
- What is being tested?
- Multi-Cancer Early Detection Test (Galleri®)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50,000 participants
- Where
- 72 sitesUnited States
- Study dates
- 12 Jul 2024to Sep 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- For Galleri + UC (Galleri-Tested Arm):
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Aged ≥50 years with Medicare coverage, including Traditional Medicare (Part A \& B or Dual Eligibles) or Medicare Advantage.
- Capable of giving informed consent that is legally effective (consent provided by a legally authorized representative is not permitted in this protocol).
- For UC (Not Galleri-tested Arm):
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Aged ≥ 50 years with Medicare coverage, including Traditional Medicare (Part A \& B or Dual Eligibles) or Medicare Advantage.
- Have had ≥ 1 UC visit
Who cannot join
- For Galleri + UC (Galleri-Tested Arm):
- Evidence of having had a previous MCED test (including but not limited to the Galleri test, e.g. CancerSeek, PanSeer). Participation in a study such as GRAIL's STRIVE study where results were not returned is not an exclusion criterion.
- Undergoing clinical evaluation for suspicion of cancer within 6 months prior to enrollment. Personal history of hematologic malignancy and/or invasive solid tumor (excluding non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin):
- Diagnosed ≤3 years before expected enrollment date and/or
- Diagnosed >3 years before expected enrollment date and never treated and/or
- Currently undergoing active cancer management (not including adjuvant hormone therapy for breast or prostate cancer).
Show all 20Show fewer
- Current pregnancy.
- Individuals who are currently inpatients at a participating site.
- Individuals who are not willing or able to comply with the protocol procedures.
- Individuals who are not currently registered patients at a participating center.
- Previous or current employees or contractors of GRAIL.
- For UC (Not Galleri-tested Arm):
- Evidence of having had a previous MCED test (including but not limited to the Galleri test, eg.CancerSeek, PanSeer). Participation in a study such as GRAIL's STRIVE study where results were not returned is not an exclusion criterion.
- Undergoing clinical evaluation for suspicion of cancer.
- Personal history of hematologic malignancy and/or invasive solid tumor (not including non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin):
- Diagnosed ≤3 years before expected enrollment date and/or
- Diagnosed >3 years before expected enrollment date and never treated and/or
- Currently undergoing active cancer management (not including adjuvant hormone therapy for breast or prostate cancer).
- Current pregnancy.
- Individuals who are currently inpatients at a participating site.
Trial locations and contacts
72 sites in 1 country. Contact the study team or a site near you to ask about taking part.
72 sites in 1 country
United States72 sites, 71 recruiting
- Recruiting
Community Health Network Anderson
Anderson, Indiana, 46011
Allison Landis, 317-621-7724, Alandis@ecommunity.com
- Recruiting
OHSU CEDAR Clinical Trials Columbia
Astoria, Oregon, 97103
Laura Ferrara, 541-645-3276, REACH@ohsu.edu
- Recruiting
OHSU CEDAR Clinical Trials Exchange
Astoria, Oregon, 97103
Laura Ferrara, 541-645-3276, REACH@ohsu.edu
- Recruiting
Morehouse School of Medicine Atlanta
Atlanta, Georgia, 30303
LaTrisha Horne, 404-789-3825, lhorne@msm.edu
- Recruiting
Morehouse School of Medicine Lee Street
Atlanta, Georgia, 30310
LaTrisha Horne, 404-789-3825, lhorne@msm.edu
- Recruiting
Morehouse School of Medicine Princeton Lakes
Atlanta, Georgia, 30331
LaTrisha Horne, 404-789-3825, lhorne@msm.edu
- Recruiting
Morehouse School of Medicine East Point
Atlanta, Georgia, 30344
LaTrisha Horne, 404-789-3825, lhorne@msm.edu
- Recruiting
Sutter Valley Hospitals Auburn
Auburn, California, 95603
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
HCA Healthcare Doctors Hospital
Augusta, Georgia, 30909
Kellie Graves, 615-507-2247, Kellie.Graves@hcahealthcare.com
- Recruiting
Ochsner Health Bocage
Baton Rouge, Louisiana, 70809
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Ochsner Health Grove
Baton Rouge, Louisiana, 70836
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
OHSU CEDAR Clinical Trials Beaverton
Beaverton, Oregon, 97006
Diana Potts, 503-418-8150, REACH@ohsu.edu
- Recruiting
Geisinger Bloomsburg Hospital - Bloomsburg
Bloomsburg, Pennsylvania, 17815
Ashley Honushefsky, 570-293-7170, reachstudy@geisinger.edu
- Recruiting
HCA Healthcare Brentwood
Brentwood, Tennessee, 37027
Kellie Graves, 615-507-2247, Kellie.Graves@hcahealthcare.com
- Recruiting
West Virginia University Health System St. Joseph
Buckhannon, West Virginia, 26201
Courtney Pilkerton, 304-285-7250, DFMresearch@wvumedicine.org
- Recruiting
OHSU CEDAR Clinical Trials BAH
Coos Bay, Oregon, 97420
Diana Potts, 503-418-8150, REACH@ohsu.edu
- Recruiting
Ochsner Health Covington
Covington, Louisiana, 70433
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Ochsner Health St. Tammany Parish
Covington, Louisiana, 70433
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Ochsner Health STCC
Covington, Louisiana, 70433
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Sutter Valley Hospitals Davis
Davis, California, 95616
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
FCCC - East Norriton
East Norriton, Pennsylvania, 19401
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
Sutter Valley Hospitals Elk Grove
Elk Grove, California, 95758
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
Community Health Network North
Fishers, Indiana, 46038
Allison Landis, 317-621-7724, Alandis@ecommunity.com
- Recruiting
Mercy Health - Fort Smith
Fort Smith, Arkansas, 72903
Damon Broyles, MercyResearchREACHStudy@Mercy.net
- Recruiting
Long Beach Memorial Orange Coast
Fountain Valley, California, 92708
Ana Fuentes, 562-760-6849, Afuentes1@memorialcare.org
- Recruiting
FCCC - Buckingham
Furlong, Pennsylvania, 18925
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
OHSU CEDAR Clinical Trials Orenco
Hillsboro, Oregon, 97124
Diana Potts, 503-418-8150, REACH@ohsu.edu
- Recruiting
OHSU CEDAR Clinical Trials Woods
Hood River, Oregon, 97031
Laura Ferrara, 541-645-3276, REACH@ohsu.edu
- Recruiting
Community Health Network East
Indianapolis, Indiana, 46219
Allison Landis, 317-621-7724, Alandis@ecommunity.com
- Recruiting
Community Health Network South
Indianapolis, Indiana, 46237
Allison Landis, 317-621-7724, Alandis@ecommunity.com
- Recruiting
Mercy Health - Joplin
Joplin, Missouri, 64804
Damon Broyles, MercyResearchREACHStudy@Mercy.net
- Recruiting
Ochsner Health Kenner
Kenner, Louisiana, 70065
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Community Health Network Kokomo
Kokomo, Indiana, 46902
Allison Landis, 317-621-7724, Alandis@ecommunity.com
- Recruiting
Ochsner Health Lafayette
Lafayette, Louisiana, 70503
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Long Beach Memorial Saddleback
Laguna Hills, California, 92653
Ana Fuentes, 562-760-6849, Afuentes1@memorialcare.org
- Recruiting
Long Beach Memorial Atlantic
Long Beach, California, 90806
Ana Fuentes, 562-760-6849, Afuentes1@memorialcare.org
- Recruiting
Ochsner Health Westbank
Marrero, Louisiana, 70072
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Ochsner Health Lafreniere
Metairie, Louisiana, 70003
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Sutter Valley Hospitals Modesto
Modesto, California, 95355
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
West Virginia University Health System Morgantown
Morgantown, West Virginia, 26501
Courtney Pilkerton, 304-285-7250, DFMresearch@wvumedicine.org
- Recruiting
West Virginia University Health System WV CTSI
Morgantown, West Virginia, 26506
Courtney Pilkerton, 304-285-7250, DFMresearch@wvumedicine.org
- Recruiting
HCA Healthcare Centennial
Nashville, Tennessee, 37203
Kellie Graves, 615-507-2247, Kellie.Graves@hcahealthcare.com
- Recruiting
HCA Healthcare Nashville
Nashville, Tennessee, 37203
Kellie Graves, 615-507-2247, Kellie.Graves@hcahealthcare.com
- Recruiting
Ochsner Health Benson
New Orleans, Louisiana, 70121
Ellen Lovell, 504-842-8196, Ellen.Lovell@Ochsner.org
- Recruiting
Mercy Health - OKC
Oklahoma City, Oklahoma, 73120
Damon Broyles, MercyResearchREACHStudy@Mercy.net
- Recruiting
Sutter Valley Hospitals PAMF Sutter
Palo Alto, California, 94301
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
FCCC - Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
FCCC - Jeanes
Philadelphia, Pennsylvania, 19111
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
FCCC - Chestnut Hill
Philadelphia, Pennsylvania, 19118
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
FCCC - Northeastern
Philadelphia, Pennsylvania, 19134
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
FCCC - Broad Street
Philadelphia, Pennsylvania, 19140
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
FCCC - Temple Main
Philadelphia, Pennsylvania, 19140
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
OHSU CEDAR Clinical Trials Portland
Portland, Oregon, 97201
Diana Potts, 503-418-8150, REACH@ohsu.edu
- Recruiting
OHSU CEDAR Clinical Trials Richmond
Portland, Oregon, 97202
Diana Potts, 503-418-8150, REACH@ohsu.edu
- Recruiting
FCCC - Huntingdon Pike
Rockledge, Pennsylvania, 19046
Camille Ragin, 267-566-3130, Camlle.ragin@fccc.edu
- Recruiting
Sutter Valley Hospitals Roseville
Roseville, California, 95661
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
Sutter Valley Hospitals Alhambra
Sacramento, California, 95816
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
Sutter Valley Hospitals Capitol Pavilion
Sacramento, California, 95816
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Active, not recruiting
HCA Healthcare St. Marks
Salt Lake City, Utah, 84124
- Recruiting
University of California San Francisco Health System
San Francisco, California, 94158
Corinne Sears, 415-205-0182, REACHMCD@ucsf.edu
- Recruiting
Sutter Valley Hospitals Santa Barbara
Santa Barbara, California, 93105
Kristina Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
Sutter Valley Hospitals PAMF Santa Cruz
Santa Cruz, California, 95065
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
Sutter Health Santa Rosa
Santa Rosa, California, 95403
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
West Virginia University Health System Shepherdstown
Shepherdstown, West Virginia, 25443
Courtney Pilkerton, 304-285-7250, DFMresearch@wvumedicine.org
- Recruiting
Mercy Health - Springfield
Springfield, Missouri, 65807
Damon Broyles, MercyResearchREACHStudy@Mercy.net
- Recruiting
Mercy Health St. Louis
St Louis, Missouri, 63141
Damon Broyles, MercyResearchREACHStudy@Mercy.net
- Recruiting
Sutter Valley Hospitals PAMF Sunnyvale
Sunnyvale, California, 94086
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
USF Morsani Center for Advanced Healthcare
Tampa, Florida, 33612
Dusan Nikolic, clinicalresearch@usf.edu
- Recruiting
OHSU CEDAR Clinical Trials Adventist
The Dalles, Oregon, 97058
Laura Ferrara, 541-645-3276, REACHstudy@ohsu.edu
- Recruiting
OHSU CEDAR Clinical Trials Dalles
The Dalles, Oregon, 97058
Laura Ferrara, 541-645-3276, REACH@ohsu.edu
- Recruiting
Sutter Valley Hospitals Fairfield
Vallejo, California, 94589
Kristina A Teresinski, 279-800-9026, clinicalresearch@sutterhealth.org
Tiffany James, 707-554-5062, clinicalresearch@sutterhealth.org
- Recruiting
OHSU CEDAR Clinical Trials Ensign
Warrenton, Oregon, 97146
Laura Ferrara, 541-645-3276, REACH@ohsu.edu
About this study
Official title: REACH Study: Galleri® in the Medicare Population.
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.
- Conditions
- Cancer
- Being tested
- Multi-Cancer Early Detection Test (Galleri®)
- Keywords
- ctDNA, Circulating tumor DNA, Screening, Cancer
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-Cancer Early Detection Test (Galleri®)Device
Blood collection and multi-cancer early detection testing with return of results.
| Study group | Role | What they receive |
|---|---|---|
| (Galleri + UC) | Experimental | Medicare beneficiaries who receive the Galleri test plus usual care (Galleri + UC). Receives: Device: Multi-Cancer Early Detection Test (Galleri®) |
| (UC) alone | No intervention | Passively-enrolled Contemporaneous Comparator Arm of Medicare beneficiaries who receive usual care (UC) alone. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence rates of stage IV cancers
Measured: Up to 3 Years
Secondary outcomes (4)
Safety: Number and type of invasive procedures performed to evaluate a cancer signal detected test result
Measured: Up to 3 Years
Galleri test performance in the Galleri + UC arm
Measured: Up to 3 Years
Adherence to guideline-recommended cancer screening in the Galleri+UC arm and UC arm over time
Measured: Up to 3 Years
Healthcare resource utilization associated with cancer diagnostic evaluations in the Galleri+UC arm and UC arm
Measured: Up to 3 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2023
- Study start12 Jul 2024
- Primary completionSep 2030 (estimated)
- Study completionSep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- The parallel arm is a passively-enrolled contemporaneous comparator cohort of Medicare beneficiaries who receive usual care without MCED screening.
- Masking
- None (open label)
- Enrolment
- 50,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GRAIL, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05673018
- Sponsor's protocol ID
- GRAIL-MA-002
- Status last verified
- Oct 2026
- First submitted
- 7 Dec 2022
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REACH Study: Galleri® in the Medicare Population.
- ClinicalTrials.gov ID
- NCT05673018
- Acronym / sponsor ID
- GRAIL-MA-002
- Conditions
- Cancer
- Keywords
- ctDNA, Circulating tumor DNA, Screening, Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- GRAIL, Inc.Industry (pharma, biotech, devices)
- Study start
- 12 Jul 2024 (actual)
- Primary completion
- Sep 2030 (estimated)
- Study completion
- Sep 2030 (estimated)
- First posted
- 5 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The parallel arm is a passively-enrolled contemporaneous comparator cohort of Medicare beneficiaries who receive usual care without MCED screening.
| Arm | Type | Receives |
|---|---|---|
| (Galleri + UC) | Experimental | Device: Multi-Cancer Early Detection Test (Galleri®)Medicare beneficiaries who receive the Galleri test plus usual care (Galleri + UC). |
| (UC) alone | No intervention | –Passively-enrolled Contemporaneous Comparator Arm of Medicare beneficiaries who receive usual care (UC) alone. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Aged ≥50 years with Medicare coverage, including Traditional Medicare (Part A \& B or Dual Eligibles) or Medicare Advantage.
- Capable of giving informed consent that is legally effective (consent provided by a legally authorized representative is not permitted in this protocol).
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Aged ≥ 50 years with Medicare coverage, including Traditional Medicare (Part A \& B or Dual Eligibles) or Medicare Advantage.
Key exclusion criteria (20 listed)
- Evidence of having had a previous MCED test (including but not limited to the Galleri test, e.g. CancerSeek, PanSeer). Participation in a study such as GRAIL's STRIVE study where results were not returned is not an exclusion criterion.
- Undergoing clinical evaluation for suspicion of cancer within 6 months prior to enrollment. Personal history of hematologic malignancy and/or invasive solid tumor (excluding non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin):
- Current pregnancy.
- Individuals who are currently inpatients at a participating site.
- Individuals who are not willing or able to comply with the protocol procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-Cancer Early Detection Test (Galleri®)Blood collection and multi-cancer early detection testing with return of results. | Device | (Galleri + UC) |
Primary outcome
Incidence rates of stage IV cancers
Time frame: Up to 3 Years
4 secondary outcomes
Safety: Number and type of invasive procedures performed to evaluate a cancer signal detected test result
Time frame: Up to 3 Years
Galleri test performance in the Galleri + UC arm
Time frame: Up to 3 Years
Adherence to guideline-recommended cancer screening in the Galleri+UC arm and UC arm over time
Time frame: Up to 3 Years
Healthcare resource utilization associated with cancer diagnostic evaluations in the Galleri+UC arm and UC arm
Time frame: Up to 3 Years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
Related trials for Cancer
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 1/2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Ovarian Cancer, Ovarian Neoplasms
RecruitingPhase 1/2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Lymphoma, Non-Hodgkin Lymphoma
RecruitingPhase 3
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
72 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multi-Cancer Early Detection Test (Galleri®) in people with Cancer, run by GRAIL, Inc. at 72 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 72 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact GRAIL Medical Information (833-694-2553, customerservice@grail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence rates of stage IV cancers (time frame: Up to 3 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.